The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
CCL
Vol.
26
No.
11
November 28, 2003
- New Therapeutic Modalities In Testing For Patients With Carcinoid Syndrome
- Nurses’ Work Environment Needs Change To Protect Patients From Errors, IOM Says
- High Radiation Dose Effective Ten Years After Treatment
- New Risk Stratification Method For Prostate Cancer Described
- Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan
- Survival After Liver Transplant Called Excellent In Study
- Tumor Size Predicts Survival In Early-Stage Lung Cancer
- B-27 Finds Improved CR For Taxotere Prior To Surgery
- Studies Link Age-Dependent Outcome To Immune Cells
- Clinical Trials Approved By NCI
TCL
Vol.
29
No.
45
December 05, 2003
- NCI advisors approved a proposal to set aside $75 million over the next five years to fund centers to study nutrition, energy balance, and physical activity. Also Board approves concepts for Cancer Disparities Networks, research in palliative care, and career awards for quantitative scientists.
- ASSIST evaluation finds proven methods help states fight tobacco.
- Latest U.S. cancer statistics cover 84% of population.
- NCI awards $42 million for prevention trials consortium.
- ACS names new officers.
- Antman, Clanton begin work at NCI.
- Sausville to lead clinical research at Maryland.
- Funding Opportunities listed.
TCL
Vol.
29
No.
46
December 12, 2003
- NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions.
- Plan posted for “public comment” on Dialogue’s Web site; who will respond, Dialogue or NCI? Cost estimate of network significantly reduced.
- Also Stillman named director, Cold Spring Harbor, Watson is chancellor.
- Pollin Prize honors four pioneers in treatment of childhood leukemia.
- December Business & Regulatory Report included in this issue.
- The Cancer Letter takes two-week break; next issue Jan. 2.
CCL
Vol.
26
No.
12
December 26, 2003
- Multi-Gene Assay Predicts Recurrence In Newly Diagnosed Breast Cancer
- FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds
- Surgery Without Radiation Found Inadequate for DCIS
- QOL With Femara Comparable To Placebo, Analysis Finds
- EMEND Improved Emesis In Men And Women, Trials Find
- Biopsies Could Be Reduced By Computer-Aided-Detection
- Chemo+Radiation Preserves Voice, RTOG Study Finds
- Low-Dose IFN Not Effective Against Melanoma, Study Finds
- NeoPharm To Begin Phase III Trial For Glioblastoma
- Elderly Men Say Physicians Are Recommending PSA Tests
- NCI-Approved Protocols Listed
